Gilead Sciences, Inc. (GILD) Stock: Price, Forecast & Analyst Target
Gilead Sciences, Inc. (GILD) — MoonshotScore 72/100 (Strong band), calculated Nov 18, 2026. Price $166.53 (-1.45%), as of the Nov 19, 2026 trading session; market cap $207B. Expected results Feb 9, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Gilead Sciences, Inc. · GILD · NASDAQ · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: Gilead sells antiviral medicines led by its HIV franchise, alongside liver-disease drugs, oncology products and cell therapies. Its investment case rests on whether launches in HIV and oncology can broaden growth while the established antiviral portfolio keeps producing cash through acquisition-related earnings disruption.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Gilead Sciences (GILD)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 9, 2027
- Altman Z 3.97 · Piotroski F 5
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 74 | Strong | |
| 74 | Strong | |
| 74 | Strong | |
| 72 | Strong | |
| 72 | Strong | |
| 72 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $166.53 | |
| Change on the day | -1.45% | |
| 52-week range | $116.88–$176.58 | |
| Market capitalisation | $207B | — |
| Price / earnings (trailing) | 13.56 | |
| Shares traded on the day | 4.97M | |
| Beta (volatility vs the S&P 500) | 0.37 |
Why Gilead Sciences scores 72
Share price, last 12 months +44.6%
$118.15 $170.87
What the price assumes
3.6% a year of free-cash-flow growth for ten years is what a $211.94B market value ( snapshot) asks for.
The growth the price implies sits inside what the business has recently delivered, so the valuation leans on that record continuing.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $13.78B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 4.1% either way.
- -3.0%Feb ’24
- -2.5%Apr ’24
- -0.5%Aug ’24
- +8.5%Nov ’24
- +8.2%Feb ’25
- -3.0%Apr ’25
- +8.3%Aug ’25
- +1.1%Oct ’25
- +2.7%Feb ’26
- -3.6%May ’26
- +0.5%Aug ’26
- +7.2%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | +7.2% | +5.3% | |
| Beat | Beat | +0.5% | +3.5% | |
| Beat | In line | -3.6% | -3.1% | |
| Beat | Beat | +2.7% | +0.7% | |
| Beat | Beat | +1.1% | +4.1% | |
| Beat | Beat | +8.3% | +7.9% | |
| Beat | Miss | -3.0% | -2.9% | |
| Beat | Beat | +8.2% | +12.7% | |
| Beat | Beat | +8.5% | +2.7% | |
| Beat | Beat | -0.5% | +0.5% | |
| Beat | Beat | -2.5% | -2.6% | |
| Miss | In line | -3.0% | -4.1% |
Beats have usually been rewarded — 7 of 11 drew a higher close the next session.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “bowel disease”, “inventory dynamics”, “clinical hold”, “favorable inventory” — none of them came up in Q2 FY2026.
- Getting louder: “inflammatory bowel” (1 → 6 mentions), “hiv portfolio” (1 → 4 mentions).
- Gone quiet: “bic len”, “d-domain binder”, “qweekly oral”, “run rate” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” rose from 2.5 to 3.9 per 1,000 words, and confident words such as “record” and “strong” fell from 4.9 to 4.4.
Management chose more careful words than a quarter earlier. Tone shifts like this often show up in the numbers a quarter or two later.
Our track record on this stock
Since the score went from 62 to 72 while the share price moved +13.5% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Fair → Strong | — | — | — | |
| Strong → Fair | — | — | — | |
| Fair → Strong | — | — | — | |
| Strong → Fair | — | — | — | |
| Fair → Strong | — | — | — |
None of the 5 band changes we have recorded has been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 67% of 58 rate it a buy; the average target sits -0.7% from the price of $166.53.
- Last 90 days: 18 rating actions, every one a reaffirmation.
- Our signals: Strong band; strongest pillar Momentum (91), weakest Financial Safety (27).
Here we and the crowd agree.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Gilead Sciences (GILD): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 21, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens and Financial health lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Gilead Sciences (GILD), and what does it report?
Short answer · as of
Gilead is a commercial medicines business rather than a development-stage biotechnology company waiting on a breakthrough.
Research dated 2026-09-12.
Revenue comes from marketed therapies across HIV, liver disease, oncology, cell therapy and other specialist indications; research and collaborations feed the future portfolio rather than define current sales.
The reporting shape remains concentrated. A large HIV product grouping dominates sales, while Trodelvy, Veklury, cell therapy and other products form smaller reported lines, so therapeutic breadth does not yet equal balanced revenue exposure.
What do the latest results show for Gilead Sciences (GILD)?
Research dated 2026-09-12.
The latest quarter paired higher revenue against the preceding and comparable periods with a deep GAAP operating and net loss. Gross profit remained high relative to sales, but the earnings-history figure was markedly less negative than GAAP diluted earnings, so those measures should not be treated as interchangeable.
Management described strong base-business performance and raised its sales outlook. It also tied an extreme effective tax rate to nondeductible acquired research expenses associated with Arcellx, Tubulis and Ouro, showing how transaction-related development spending can damage statutory earnings even when product demand strengthens.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $8.30B Oct 29, 2026
- Latest report · revenue estimate
- $7.81B Oct 29, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 29, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 29, 2026 | $8.30B | $7.81B | $2.5500 | $2.1900 |
| Aug 4, 2026 | $7.80B | $7.40B | −$6.7500 | −$7.2500 |
| May 7, 2026 | $6.96B | $6.91B | $2.0300 | $1.9100 |
| Feb 10, 2026 | $7.92B | $7.69B | $1.8600 | $1.8100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $7.77B | $3.05B | $2.43 (diluted) |
| Q4 FY2025 | $7.92B | $2.18B | $1.74 (diluted) |
| Q1 FY2026 | $6.96B | $2.02B | $1.61 (diluted) |
| Q2 FY2026 | $7.80B | -$10.50B | -$8.44 (diluted) |
What are the financial strengths and risks for Gilead Sciences (GILD)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Gilead retains strong gross economics and substantial operating cash generation, with capital expenditure modest beside operating inflows. Near-term liquidity ratios remain above parity, and the distress screen does not indicate immediate financial strain.
The balance sheet is less forgiving than the cash flow statement alone suggests. Debt greatly exceeds cash and short-term investments, while liquidity has fallen sharply across the reported window despite positive operating cash flow.
Product concentration compounds that financial constraint. HIV supplies most reported product revenue, leaving Trodelvy and cell therapy responsible for broadening the earnings base if the established antiviral franchise loses momentum.
Data-derived red flags
- Negative return on equity (-22.4%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Gilead Sciences (GILD)?
Short answer · as of
The next earnings report is expected on Feb 9, 2027.
Research dated 2026-09-12.
Watch whether the announced HIV and oncology launches convert commercial activity into visible product growth, and whether oncology and cell therapy begin reducing reliance on the dominant HIV grouping. Launch announcements matter less than sustained contribution to reported sales.
Revenue strength also needs to reconnect with GAAP profitability. Useful confirmation would include stable gross economics, operating earnings returning to positive territory, continued operating cash generation and an end to steep liquidity erosion; the scheduled earnings release provides the nearest checkpoint.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Gilead Sciences compare with its peers?
Short answer
Gilead Sciences's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Compared with development-stage biotechnology businesses, Gilead already has a large marketed portfolio and recurring cash generation that can fund research and transactions. Compared with broadly diversified pharmaceutical groups, however, its revenue remains unusually anchored in HIV.
Trodelvy and the cell-therapy portfolio give Gilead a distinct oncology expansion path, but they remain much smaller than the HIV grouping. The company therefore combines mature antiviral economics with the execution demands of building a commercially meaningful oncology business.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1351.12 Nov 19, 2026 | $1.20T | 98 5-pillar Nov 18, 2026 | |
| $38.87 Nov 19, 2026 | $171B | 87 5-pillar Nov 18, 2026 | |
| $46.06 Nov 19, 2026 | $111B | 87 5-pillar Nov 18, 2026 | |
| $175.41 Nov 19, 2026 | $272B | 85 5-pillar Nov 18, 2026 | |
| $58.34 Nov 19, 2026 | $119B | 85 5-pillar Nov 18, 2026 | |
| $438.82 Nov 19, 2026 | $237B | 84 5-pillar Nov 18, 2026 | |
| $283.54 Nov 19, 2026 | $501B | 83 5-pillar Nov 18, 2026 | |
| $267.14 Nov 19, 2026 | $643B | 83 5-pillar Nov 18, 2026 | |
| $151.22 Nov 19, 2026 | $286B | 82 5-pillar Nov 18, 2026 | |
| $47.82 Nov 19, 2026 | $95.9B | 77 5-pillar Nov 18, 2026 | |
| Gilead Sciences (GILD) — this page | $166.53 | $207B | 72 |
| $227.56 Nov 19, 2026 | $160B | 71 5-pillar Nov 18, 2026 | |
| $132.81 Nov 19, 2026 | $327B | 69 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $126.00 – $196.00
- Consensus target
- $167.47
- Median target
- $172.00
Consensus record · Captured .
Measured against a quoted price of $166.53 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 100
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 47
- Other transactions
- 53
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GILD in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.21% | $47.91M | Added +10.5% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Gilead Sciences (GILD)?
Common Questions About GILD (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How dependent is Gilead on Biktarvy and its wider HIV portfolio?
Biktarvy sits within a much larger reported HIV grouping that supplies most product revenue. Trodelvy and cell therapy are meaningful but remain much smaller, so changing the sales mix depends on their expansion.
Why did Gilead’s GAAP result turn negative while sales grew?
Sales strengthened, yet the latest period produced large operating and net losses. Management identified nondeductible acquired research expenses associated with Arcellx, Tubulis and Ouro as a major distortion to the effective tax rate, while the reported earnings measure remained less negative than GAAP diluted earnings.
How important are Yescarta and Tecartus to Gilead’s business mix?
Yescarta and Tecartus anchor the reported cell-therapy business and extend Gilead beyond antiviral medicines. Cell therapy is already a meaningful product line, though still far smaller than the HIV grouping.
What would Gilead’s planned HIV and oncology launches change?
Successful launches could reinforce the established HIV franchise while increasing oncology’s contribution to growth. Evidence would appear in product sales and a broader revenue mix, not merely in launch activity.
What is the GILD stock price today?
The last price recorded for Gilead Sciences, Inc. (GILD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the GILD price target?
The analyst consensus price target for Gilead Sciences, Inc. (GILD), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 43 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold GILD
Funds in our ETF coverage that list GILD among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Brookstone Dividend Stock ETF (BAMD) | 4.10% | |
| iShares Evolved U.S. Innovative Healthcare ETF (IEIH) | 4.01% | |
| PBPH ETF | 3.98% | |
| VHT ETF | 2.68% | |
| Pacer US Cash Cows 100 ETF (COWZ) | 2.27% | |
| American Century STOXX U.S. Quality Value ETF (VALQ) | 1.75% | |
| State Street SPDR S&P Biotech ETF (XBI) | 1.49% |
